Paul Wilde
Overview
Explore the profile of Paul Wilde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cascavilla N, De Stefano V, Pane F, Pancrazzi A, Iurlo A, Gobbi M, et al.
Drug Des Devel Ther
. 2015 Jun;
9:2687-94.
PMID: 26028965
A JAK2(V617F) mutation is found in approximately 55% of patients with essential thrombocythemia (ET), and represents a key World Health Organization diagnostic criterion. This hypothesis-generating study (NCT01352585) explored the impact...
2.
Kanakura Y, Miyakawa Y, Wilde P, Smith J, Achenbach H, Okamoto S
Int J Hematol
. 2014 Aug;
100(4):353-60.
PMID: 25160063
Essential thrombocythemia (ET) is usually managed by anti-platelet therapy. European guidelines recommend that patients with ET at high risk of developing thrombohemorrhagic events should be placed on cytoreductive therapy (CRT)....
3.
Urena-Torres P, Prie D, Keddad K, Preston P, Wilde P, Wan H, et al.
BMC Nephrol
. 2014 Jun;
15:71.
PMID: 24885942
Background: High levels of circulating fibroblast growth factor 23 (FGF23) are associated with chronic kidney disease (CKD) progression and high mortality. In the Phosphate Reduction Evaluation of FGF23 in Early...
4.
Rey J, Viallard J, Keddad K, Smith J, Wilde P, Kiladjian J
Eur J Haematol
. 2013 Oct;
92(2):127-36.
PMID: 24118452
Objectives: To identify switch modalities used when initiating second- or third-line anagrelide for essential thrombocythemia (ET), assess whether anagrelide is initiated consistently with Summary of Product Characteristics (SPC) recommendations, and...